Christopher Fiack, MD
Pulmonary Disease · Honolulu, HINPI 1891716072
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $135 of the $180 with a category attached, or 74.6%. 4 manufacturers reported payments, led by United Therapeutics Corporation at 38.8% of the total. That places this record below the midpoint for pulmonary disease clinicians in HI, where the typical reported total is $1,248.
Across 8 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$70
- GSK$45
- Actelion Pharmaceuticals US, Inc.$44
- Getinge USA Sales, LLC$21
Across 11 payments — averaging $5103.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Octapharma USA, Inc.$44K
- Actelion Pharmaceuticals, Ltd$12K
What the payments were for
- Food & beverage$13575%
- Education$4625%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 2 | $70 |
| GSK | 3 | $45 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Getinge USA Sales, LLC | 1 | $21 |
How this compares
$180 in reported general payments places this provider in the 20th percentile of 44 pulmonary disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 121 | $1,585,451 |
| Tyvaso DpiTreprostinil | 45 | $1,121,802 |
| Orenitram ErTreprostinil Diolamine | 32 | $581,380 |
| Ambrisentan | 107 | $331,354 |
| AdempasRiociguat | 23 | $320,969 |
| Tadalafil | 82 | $93,285 |
| Sildenafil Citrate | 146 | $34,717 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $44 | $1,585,451121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 44 pulmonary disease providers in Hawaii.
Other pulmonary disease in Honolulu
- Takkin LoHonolulu$324K
- Bradley TokeshiHonolulu$41K
- Ernie YimHonolulu$20K
- Eric CrawleyHonolulu$17K
- Samuel EvansHonolulu$15K
- Ronson SatoHonolulu$14K
- Alvin FuruikeHonolulu$10K
- James YangHonolulu$8K
- Katsufumi NishidaHonolulu$8K
- Sheri Shimizu-SaitoHonolulu$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.